Management of Advanced and Castration Resistant Prostate Cancer Supplement
In conjunction with the Medical College of Wisconsin (MCW), The Canadian Journal of Urology (CJU) and Carden Jennings Publishing Co., Ltd. (CJP) has created and published a CME-accredited journal supplement featuring fifteen (15) articles on advanced and castration-resistant prostate cancer. It is physician-led, multi-supported, and designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the treatment of prostate cancer. The Canadian Journal of Urology: International Supplement is entitled: Management of Advanced and Castration Resistant Prostate Cancer.
Program Goal
The goal of this educational program is to equip urologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer with the up-to-date clinical knowledge and tools they need to best treat their patients with advanced and castration-resistant prostate cancer.
Target Audience
The activity is oriented to a target audience of physicians and meidcal care professionals specializing in the diagnois and treatment of prostate cancer.
Learning Objectives
- Describe the changing landscape of advanced prostate cancer
- Evaluate the use of imaging technologies in castrate resistant prostate cancer
- Assess the emerging role of intermittent hormonal therapy in treating advanced prostate cancer
- Define recent developments in prostate cancer treatment that can impact patient quality-of-life outcomes
Editor:
Leonard G. Gomella, MD
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Clinical Director Jefferson Kimmel Cancer Center Network
Thomas Jefferson University
Philadelphia, PA, USA
Co-Editors:
Daniel P. Petrylak, MD
Professor, Medical Oncology
Director, Prostate and Genitourinary Cancers
Yale Cancer Center
New Haven, CT, USA
Bobby Shayegan, MD
Assocate Professor, Urologic Oncology
Deputy Chief of Surgery SJHH
McMaster University
Hamilton, ON Canada
INTRODUCTION – Leonard G. Gomella, Daniel P. Petrylak, Bobby Shayegan
Current management of advanced and castration resistant prostate cancer
Primary Authors
Christopher Evans, MD
Professor and Chair
Department of Urologic Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA USA
The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions
E. David Crawford, MD
Professor of Surgery and Radiation Oncology
Head of Section on Urologic Oncology
University of Colorado Health Sciences Center
Denver, CO USA
Traditional androgen ablation approaches to advanced prostate cancer: new insights
Judd W. Moul, MD, FACS
Director, Duke Prostate Center
Division of Urologic Surgery
Duke University Medical Center
Durham, NC USA
Utility of LHRH antagonists for advanced prostate cancer
Bobby Shayegan, MD FRCSC
Associate Professor
Urologic Oncology
Deputy Chief of Surgery SJHH
Head Cancer Surgery SJHH
Chair Robotic Surgical Programme SJHH
McMaster University
Hamilton, ON Canada
Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice
Eric Winquist MD MSc
Professor, Department of Oncology
Western University
Lead, Lawson Translational Cancer Research Team
Medical Director, Clinical Cancer Research Program
Chair, London Medical Oncology Associates
London Health Sciences Centre
London, ON Canada
Secondary hormonal manipulation in castration resistant prostate cancer
Lawrence Schwartz, MD
Professor and Chairman
Department of Radiology
Columbia University Medical Center
New York, NY USA
Imaging approaches with advanced prostate cancer: Techniques and timing
Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director, Jefferson Kimmel Cancer Center
Clinical Director Jefferson Kimmel Cancer Center Network
Thomas Jefferson University
Philadelphia PA USA
Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy
Daniel W. Lin, MD
Professor
Chief of Urologic Oncology
Bridges Endowed Professorship in Prostate Cancer Research
Department of Urology
University of Washington
Seattle, WA USA
Practical guide to the use of abiraterone in castration resistant prostate cancer
W. Kevin Kelly, DO
Director of the Solid Tumor Oncology
Department of Medical Oncology
Associate Director of Translational Research
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA, USA
Practical guide to the use of enzalutamide
Robert B. Den, MD
Radiation Oncologist
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA, USA
Practical guide to the use of radium 223-dichloride
Daniel P. Petrylak, MD
Director, Prostate and Genitourinary Cancers
Co Director, Signal Transduction Program
Yale Cancer Center
New Haven, CT USA
Practical guide to the use of abiraterone in castration resistant prostate cancer
Prof. Bertrand Tombal
Chairman
Division of Urology
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Practical guide to bone health in the spectrum of advanced prostate cancer
Robert Dreicer, MD, MS, FACP
Chairman, Department of Solid Tumor Oncology
Taussig Cancer Institute
Professor of Medicine
Cleveland Clinic of Lerner College of Medicine
Cleveland, OH USA
How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer
Ganesh Raj, MD, PhD
Oncology Fellowship Director
Assistant Professor
UT Southwestern Medical Center
Dallas, TX USA
Emerging therapies in castration resistant prostate cancer
Available Credit
- 16.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 16.00 Hours of ParticipationHours of Participation credit.